Jade Biosciences Inc., a biotechnology company specializing in therapies for autoimmune diseases, announced plans to initiate a clinical study of its anti-APRIL monoclonal antibody, JADE101, in healthy volunteers in the latter half of 2025. This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarker suppression of JADE101, specifically targeting APRIL and IgA. Interim results from this study are expected in the first half of 2026, which will aid in determining appropriate dosing for future studies in patients with IgA nephropathy (IgAN). Preclinical data, presented at the 62nd European Renal Association Congress, highlighted JADE101's potential for best-in-class efficacy with convenient dosing intervals. A conference call and webcast regarding these developments were held on June 9, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.